Inbrija

Warning

Contraindicated in patients taking nonselective monoamine oxidase (MAO) inhibitors

Contraindications

• Nonselective monoamine oxidase (MAO) inhibitors
• Hypertension can occur if these drugs are used concurrently

Adverse Reactions

• Falling asleep during activities of daily living and somnolence
• Withdrawal-emergent hyperpyrexia and confusion
• Hallucinations/psychosis
• Impulse control/compulsive behaviors
• Dyskinesia
• Bronchospasm in patients with lung disease

General Guidance

The maximum dose per OFF period is 84 mg, and the maximum recommended daily dosage of Inbrija is 420 mg

Pregnancy

• No adequate data on the developmental risk associated with the use of Inbrija in pregnant women
• Carbidopa/levodopa has been shown to be developmentally toxic in animal studies

Nursing Mothers

Pediatric Use

• Safety and effectiveness in pediatric patients have not been established

Geriatric Use

• Of the Parkinson's disease patients in Study 1 who took Inbrija 84 mg, 49% were 65 years of age and older
• Age-related differences in adverse reactions were reported in patients 65 years of age and older vs. in patients under 65 years of age